TrialVaccine2025

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).

Germán Áñez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.